The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study

Table 2 Vaccination parameters

Age class	Vaccine efficacy^a		Reference	Vaccination coverage			Reference (initial value)
Age class	Vaccine efficacy^a		Reference	Scenario 1	Scenario 2
	TIV	LAIV		TIV	TIV	LAIV
1 year	11.0%	N/A	Vesikari et al. [41]	19.2%	19.2%	---	Blank et al. [30]
2 years	59.0%	80.0%	Jefferson et al. [19]; Rohrer et al. [18]	19.2%	19.2%	22.4-50%^b	Blank et al. [30]
3-6 years	59.0%	80.0%	Jefferson et al. [19]; Rohrer et al. [18]	22.4%	N/A	22.4-50%^b	Blank et al. [30]
7-10 years	59.0%	80.0%	Jefferson et al. [19]; Rohrer et al. [18]	23.6%	N/A	23.6-50%^b	Blank et al. [30]
11-17 years	59.0%	80.0%	Jefferson et al. [19]; Rohrer et al. [18]	11.0%	N/A	11.0-50%^b	Blank et al. [30]
18-59 years, normal risk	68.0%	N/A	Monto et al. [29]	14.5%	14.5%	N/A	Blank et al. [30]
18-59 years, elevated risk	58.0%	N/A	Jefferson et al. [28]	29.8%	29.8%	N/A	Blank et al. [31]
60-64 years	58.0%	N/A	Jefferson et al. [28]	33.1%	33.1%	N/A	Blank et al. [31]
65-69 years	58.0%	N/A	Jefferson et al. [28]	47.6%	47.6%	N/A	Blank et al. [31]
70 years and over	58.0%	N/A	Jefferson et al. [28]	53.4%	53.4%	N/A	Blank et al. [31]

TIV trivalent inactivated influenza vaccine; LAIV live-attenuated influenza vaccine; N/A not applicable.
^aVaccine efficacy determines the fraction of (previously susceptible) vaccinees who are immune due to vaccination at the peak of the following transmission season (i.e. 100 days after vaccination).
^bLAIV coverage increases in three annual steps from the initial to the final percentage.

ISSN: 1471-2334